Last reviewed · How we verify
GC3110A vaccine
GC3110A is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.
GC3110A is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for Advanced or metastatic cancer (specific indication under investigation in phase 3).
At a glance
| Generic name | GC3110A vaccine |
|---|---|
| Also known as | GC3110A |
| Sponsor | Green Cross Corporation |
| Drug class | Therapeutic cancer vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The vaccine works by activating dendritic cells and T-cell responses against tumor antigens, enabling the patient's immune system to target and eliminate cancer cells. This approach aims to provide durable anti-tumor immunity by training the adaptive immune system to recognize cancer-specific epitopes.
Approved indications
- Advanced or metastatic cancer (specific indication under investigation in phase 3)
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Myalgia
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age (PHASE3)
- A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older (PHASE3)
- A Multicenter, Double-blind, Parallel Phase III Study (PHASE3)
- A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GC3110A vaccine CI brief — competitive landscape report
- GC3110A vaccine updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI